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Abstract 
Objectives. To examine the risk of atrial fibrillation (AF) at the time of first diagnosis of gout 
compared to matched controls and to follow incident gout patients and their matched controls 
after diagnosis to compare their subsequent risk of AF.   
Methods. 45,378 incident gout patients and 45,378 age-, sex-, practice-, registration year- 
and index year-matched controls were identified from the UK Clinical Practice Research 
Data-link. Index dates were initial diagnosis date for gout patients and their matched controls. 
The risk of AF at diagnosis (odds ratios [ORs], using conditional logistic regression) and after 
the diagnosis of gout (hazard ratios [HRs], using Cox proportional models) were estimated, 
adjusted for body mass index, smoking, alcohol consumption, ischaemic heart disease, heart 
failure, heart valve disease, hyperthyroidism and other comorbidities and medications.  
Results. The prevalence of AF at index date in gout patients (male, 72.3%; mean age, 62.4 ± 
15.1 years) was 7.42% (95% confidence interval [CI], 7.18%–7.66%) and in matched 
controls 2.83% (95% CI, 2.67%–2.98%). The adjusted OR (95% CI) was 1.45 (1.29–1.62). 
The cumulative probability of AF at 1, 2, 5 and 10 years after index date was 1.08%, 2.03%, 
4.77% and 9.68% in gout patients and 0.43%, 1.08%, 2.95% and 6.33% in controls (log-rank 
test, p < 0.001). The adjusted HRs (95% CIs) was 1.09 (1.03–1.16). 
Conclusions. This population-based study indicates that gout is independently associated 
with a higher risk of AF at diagnosis and the risk is also higher after the diagnosis. 
Keywords: gout, atrial fibrillation, relative risks, population study, CPRD 
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Key messages: 
1. Gout patients often have multiple comorbidities.  
2. Gout is independently associated with a higher risk of atrial fibrillation. 
3. Electrocardiogram is warranted for gout patients at diagnosis. 
 
Introduction 
Gout is the most common inflammatory arthritis worldwide and affects one in 40 individuals 
in the UK [1]. In addition to episodic acute arthritis, gout also results in chronic joint damage, 
subcutaneous tophi and peri-articular inflammation [2]. It is generally accepted that gout is 
highly associated with the features of metabolic syndrome[3] and chronic renal impairment 
[4]. In addition, gout patients are also at higher risk for developing many different conditions, 
such as cardiovascular [5-12], metabolic [3, 11, 13], renal [4, 11], and many other 
comorbidities [14-16], which collectively lead to an increased mortality [17, 18]. A recent 
study of co-morbidities that associate with gout also provided evidence for an association 
with cardiac arrhythmias [11], an observation not reported previously.  
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia present in clinical practice 
[19]. In the UK, the incidence of chronic AF was reported in 2002 as 1.7 per 1,000 person-
years, and this increased markedly with age [20]. Affected patients are at increased risk of 
heart failure, thromboembolic events such as stroke, and increased mortality [21, 22]. The 
Framingham study reported a 4 to 5-fold risk for stroke in patients with AF [23]. In addition, 
AF is also associated with a 2-fold risk of silent stroke [24]. The major risk factors 
recognised for AF include heart failure, ischaemic heart disease, hypertension, thyroid 
disease, heavy drinking and obesity [25]. Interestingly, stroke and many predictors for AF are 
also common comorbidities in gout patients [11], suggesting that there may be a potential link 
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between gout and AF. For example, a recent study has indicated that hyperuricaemia is 
associated with a larger left atrial dimension [26, 27] and a greater risk of AF [26-28]. 
However, despite some evidence that hyperuricaemia, the prerequisite for gout, may be a risk 
factor for AF, the association between gout and AF has not been formally studied.   
Therefore, using data representative of the general population of UK from the Clinical 
Practice Research Data-link (CPRD), this study aimed to examine the risk of AF at the time 
of first diagnosis of gout compared to matched controls. We further followed incident gout 
patients and their matched controls after diagnosis to compare their subsequent risk of AF.   
 
Methods 
We hypothesised that gout patients have a higher risk of AF at the time of first diagnosis and 
that the risk would continue to be higher after the diagnosis of the disease. We addressed this 
hypothesis using both retrospective (prior to diagnosis) and prospective case control study 
(after diagnosis) within the CPRD. The study complies with the Declaration of Helsinki and 
the protocol was approved by the Independent Scientific Advisory Committee for MHRA 
Database Research (protocol 11-021R). All data in this study were totally anonymised 
therefore patient consents are exempted.  
Data source 
In the UK, general practitioners are the ‘gatekeepers’ for all resources of the health care 
system. CPRD is a database containing primary care data prospectively collected by general 
practitioners in 684 practices who were trained to record medical information to ensure the 
accuracy of the data but were unware of the information of research based on the database. 
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Currently the database contains data on more than 15 million people across the UK and is 
broadly representative of the UK general population in age and sex structure [29]. The 
database has been described previously[29] and has been validated for many diagnoses, 
including gout[30] and many other medical conditions [30-34]. A recent systematic review 
reported that the median percentage of cases confirmed by validation was 89% (33-100%) 
[33]. Importantly, 87% of diagnoses from secondary care specialists were captured and 
recorded [33]. The database contains comprehensive information on patient demographics, 
lifestyle factors, medical diagnoses, results of investigations and examinations and prescribed 
medications. The CPRD is also linked to additional data sources including secondary care, 
the Office for National Statistics cause of death data and information from specific disease 
registries.  
Study design 
In this study, our source population was based on the August 2014 version of CPRD. The 
study population consisted of all incident gout patients diagnosed between 1997 and 2005 
who had at least 3 years of continuous registration. Each incident gout patient was matched at 
random to one control patient who was registered in the same practice and did not have gout 
and any prescription of urate-lowering treatment. Control patients were frequency-matched in 
a 1:1 ratio to incident gout patients by year of birth (±2 years), gender, general practice and 
year of first continuous registration (±2 years) at this CPRD practice. The same index date 
was assigned to each of the matched controls. As with incident gout patients the matched 
controls had at least three years of registration prior to the index date. For prospective 
analysis, follow-up time started from index date and ended when they had AF, died, 
transferred out of the practice, or the last data collection date of the practice they registered, 
whichever came first. 
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Study groups 
We classified patients according to Read codes, which are diagnostic codes used by general 
practitioners to define diseases, procedure and other patient characteristics in UK primary 
care. Patients with gout were identified using a code list for gout, which our group has been 
using consistently[1, 11, 35] and which was validated previously with an overall 
ascertainment rate of 90% [30]. The case definition was based on physician-diagnosis using 
18 READ codes indicative of incident gout [1]. The gout diagnosis in the CPRD has been 
validated previously by a review of medical records of 10 confirmed and 28 probable gout 
patients showing that 10 out of 10 confirmed cases and 24 out of 28 probable cases were true 
gout patients (overall ascertainment rate 90%) [30]. In the UK, ULT is indicated only for gout 
or uric acid nephrolithiasis. However, some patients did receive ULT prior to their first 
recording of gout diagnosis or without any diagnosis. These patients were excluded from this 
study.  
Atrial fibrillation outcome assessment 
Our primary outcome of interest was AF based physician diagnosis. This case definition has 
been validated previously [20, 36]. These validation studies contacted practitioners for a 
questionnaire asking them to classify 1714 AF patients according to a set of criteria. Among 
1606 valid questionnaires, only 66 patients were confirmed not to have AF [20, 36]. 
Assessment of covariates  
We collected life style characteristics (alcohol use, smoking and body mass index [BMI]), 
comorbidities (hypertension, myocardial infarction, congestive heart failure, peripheral 
vascular disease, cerebrovascular disease, heart valve disease, hyperthyroidism, dementia, 
chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, mild liver disease, 
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liver disease, diabetes mellitus, renal diseases, cancer and anaemia), medication use 
(antihypertensive, glucocorticoid, statin, lipid-lowering agents, hypoglycaemic agents, 
insulin, aspirin, anticoagulants and hormone replacement treatment) and number of 
consultations in the one year prior to the index date. Life style characteristics were 
ascertained using the nearest possible measurement prior to the index date. Comorbidities 
were ascertained within 10 years and medications and the number of visits to practitioners 
was ascertained within one year prior to the index date.  
Statistical analysis 
Patient characteristics at index date were compared between gout patients and matched 
controls. The prevalence of AF was calculated using the number of people ever diagnosed 
with AF during the past three-year period before the index date as the numerator and the 
number of incident gout patients or matched controls as denominators. Odds ratios (OR) and 
95% confidence intervals (CI) were used to estimate the association between gout and AF at 
diagnosis. Conditional logistic regression was used to adjust for the aforementioned 
covariates. Missing data for BMI, smoking and alcohol status were coded as ‘unknown’. Both 
gout patients and matched controls were followed up from the index date to the earliest date 
of occurrence of AF, death, transfer out or end of study (31 December 2013), whichever came 
first. Kaplan–Meier product-limit analysis were used to estimate the cumulative probability 
of AF in people with incident gout and matched controls. HRs with 95% CIs were calculated 
for AF using a Cox proportional hazards model. Only people without AF at index date were 
considered in the Cox model. We checked the proportional hazards assumptions by 
examining the log-log survival curves in our models. The HRs were adjusted by the 
aforementioned covariates. Data were missing for alcohol use, smoking and BMI in 24.76%, 
17.62% and 17.62% patients, respectively. These lifestyle characteristics were generally 
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obtained when patients visit GPs. Therefore we assumed that data were missing at random 
(the missing pattern does not depend on the unobserved data). We used multiple imputation to 
handle these missing data using SAS MI procedure. The imputation model used logistic 
regression for alcohol and smoking and regression for BMI. We include all lifestyle, 
comorbidity and consultation frequency variables in the imputation model. The procedure 
generated 5 imputed datasets. The datasets were pooled for logistic regression and Cox 
proportional hazards models using Rubin’s strategy [37]. We performed a sensitivity analysis 
using different method handling missing values (multiple imputation and setting a new 
category for missing value). All statistical analyses were performed using SAS statistical 
software, version 9.3.  
 
Results 
Study population 
We identified 45,378 incident gout patients during the period 1997 to 2005 (mean age 62.4 ± 
15.1 years; 72.3% being men). Female patients were older than male patients and had more 
comorbidities and medications use. They were 1:1 matched to 45,378 controls with the same 
age and sex structure (Table 1). The median observation periods (interquartile range) before 
and after index date were 15 (9–27) and 9 (5–12) years with no statistical difference between 
gout patients and controls. Gout patients consumed more cigarettes and alcohol and had a 
higher BMI, Charlson score and more general practice than controls. The prevalence of 
hypertension, ischaemic heart disease, cerebrovascular disease, heart failure and heart valve 
disease was significantly higher in gout patients than controls in both genders. More gout 
patients were prescribed medications (Table 1). 
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Retrospective observation 
At time of index date, the proportion of people having AF was significantly higher in incident 
gout patients (7.42%; 95% CI, 7.18%–7.66%) than in controls (2.83%; 95% CI, 2.67%–
2.98%; p<0.001). The prevalence of AF at index date was higher in both men and women 
with gout than in their respective controls (Table 2). Using a conditional logistic regression 
models, the unadjusted OR was estimated to be 2.89 (95% CI, 2.70–3.09) for AF. After 
consideration of all covariates including traditional risk factors for AF such as cardiovascular 
diseases and hyperthyroidism, gout was still associated with an increased odds for AF, with 
an adjusted  OR of 1.45 (95% CI, 1.29–1.62). Separate estimates for men and women were 
shown in table 2. Both men and women with gout had a higher AF prevalence than that in the 
controls.  
Follow-up data after index date 
As shown in Figure 1, the cumulative probability for incident AF was significantly higher in 
gout patients than in matched controls at all time since index date (log-rank test p<0.001). 
The cumulative probability of AF in gout patients who were free of AF at first presentation 
was 1.08% at one year, 2.03% at 2 years, 4.77% at 5 years and 9.68% at 10 years after index 
date. In comparison, the cumulative probability of AF in controls was 0.43%, 1.08%, 2.95% 
and 6.33% at 1, 2, 5, and 10 years after index date (log-rank test p < 0.001). After a median 
follow-up of 9 years, 3,534 gout patients and 2,322 matched controls who were free of AF at 
index date developed AF. The matched HR was 1.66 (1.59–1.74) and adjusted HR was 1.09 
(95% CI, 1.03–1.16) respectively. Separate estimates for men and women were shown in 
Table 3. The unadjusted and adjusted HR estimates were similar in magnitude for both men 
and women. 
Sensitivity analysis 
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Next, we undertook a sensitivity analysis by replacing missing values (alcohol consumption, 
smoking and BMI categories) by a new category and performing logistic regression and Cox 
proportional models again. As shown in Table 4, all estimates were very similar to estimates 
in the primary analysis. 
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Discussion 
This study used a large primary care database in the UK to compare the risk of AF in gout 
patients with matched controls at diagnosis (index date) and also to estimate the risk of future 
AF diagnosis. The prevalence of AF was two-fold higher in gout patients than controls at 
diagnosis. Furthermore, approximately 12% of gout patients developed AF within 5 years 
from the diagnosis whereas only 6% of matched controls developed AF. The incidence of AF 
was 60% higher in AF-free gout patients than matched controls. After controlling for known 
predictors for AF (such as ischaemic heart disease, heart failure, valvular heart disease and 
hyperthyroidism) [25], other comorbidities and medication use, gout was still independently 
associated with AF although the magnitude of association was diminished. Gout is probably 
an independent risk factor for AF, despite it also being associated with many comorbidities 
that also contribute to development of AF. Overall, the burden of AF is very high at diagnosis 
of gout and the risk of developing new comorbidity is also elevated in incident gout patients 
compared to the general population.  
Currently, there is no explicit explanation for the link between gout and AF. The potential 
mechanism underlying the increased risk of AF in gout patients is hyperuricaemia. Increasing 
evidence suggests that uric acid participates in the atrial remodelling process which enhances 
the risk of AF [38]. Previous studies suggesting a higher risk of AF in individuals with 
hyperuricaemia are scarce. Cross-sectional studies generally found a higher prevalence of AF 
in hyperuricaemic patients with or without heart diseases [39-43]. However, these studies 
were retrospective in nature and many were based on hospital records, which may introduce 
selection bias. The prospective studies supporting the link between hyperuricaemia and AF 
include the Atherosclerosis Risk in Communities study which observed 15,382 AF-free 
patients aged 45 to 64 years for a median of 16.8 years [44]. The study found that one 
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standard deviation (SD) increase in serum uric acid (SUA) levels is associated with a HR of 
1.56 for AF in black Americans but no significant association was identified for white 
Americans. A recent study following 400 patients with type 2 diabetes found that a 1-SD 
increment SUA level was associated with approximately 2.5-fold increase in the risk of 
incident AF [45]. Our finding with a higher risk of AF in gout patients at diagnosis supports 
the assumption that hyperuricaemia is associated with an increased risk of AF because 
invariably gout patients are exposed to long-term hyperuricaemia.  
After diagnosis, the incidence of AF in gout patients is still 60% higher than their matched 
controls. However, the adjusted HRs for AF diminished, despite it still being statistically 
significant. There are two potential explanations. Firstly, some patients may be treated by 
urate-lowering treatment which may then reduce their risk of developing AF.  However, 
against this is the finding in our recent studies that the majority of gout patients did not 
receive urate-lowering treatment [1] even long after the initial diagnosis [35]. Secondly, 
hyperuricaemia not only increase the risk of AF but also increased the risk of other 
cardiovascular diseases that hasten the development of AF. For example, gout is consistently 
associated with heart failure [11, 12] and ischaemic heart disease [5-9], both of which are 
established risk factors for AF [25]. Since many gout patients already had such risk factors 
for AF at or shortly after diagnosis [11], the effect of gout on AF may be diluted. 
Nevertheless, the absolute risk of AF in gout patients is approximately 60% more than age- 
and sex- matched controls. Therefore, vigilance for AF should be entertained for all gout 
patients at diagnosis or thereafter.  
AF is one of the most important risk factor for stroke [46]. Our findings linking gout and AF 
support previous studies documenting that gout patients have a higher risk of stroke [10, 11]. 
We previously compared the risks of comorbidities in 39,111 patients with incident gout and 
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39,111 matched controls using the CPRD and found that gout was associated with an OR of 
1.50 for stroke at diagnosis and with a HR for 1.29 for stroke after diagnosis [11]. This 
finding was supported by another study linking CPRD and data from secondary care [10]. 
Collectively these findings indicate that gout patients are at risk for both AF and stroke. Our 
study cannot differentiate the impact of gout and AF on stroke but gout is known to have a 
high burden of cardiovascular comorbidities in addition to AF [11], so cardiovascular 
vigilance seems warranted and current guidelines and recommendations [47, 48] support this 
practice. However, none of these practice recommendations and guidelines specifically 
advise undertaking an electrocardiogram on gout patients, which is an inexpensive screening 
for AF. Therefore, this study supports the case for a clinical cardiovascular assessment and 
inclusion of an electrocardiogram as a part of the initial assessment of gout patients at 
diagnosis and close observation, for example by annual assessment, for the occurrence of 
incident AF, especially for the elderly and those having other AF risk factors. 
There are several limitations to this study. Firstly, misclassification bias could exist since the 
identification of gout patients was based on physician diagnosis, rather than according to 
classification criteria [49, 50] or to the 'gold standard' of urate crystal identification. However, 
the validity of gout diagnosis in the CPRD has been investigated and found to be high [30]. 
Similarly there may have been some misclassification of AF, though again this diagnosis has 
been validated previously and the recordings of a diagnosis of AF are generally reliable [20, 
36]. In addition, there is no reason to suspect a differential misclassification of AF between 
gout and non-gout patients. Secondly, differential ascertainment bias between incident gout 
patients and controls cannot be excluded entirely. However, we have adjusted for consultation 
frequency in our models and the observation periods before and after the index date were 
comparable between cases and controls. Thirdly, potential confounders may exist and biased 
our results toward null. For example, the Framingham Heart Study incorporate age, sex, 
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systolic blood pressure, treatment for hypertension, PR interval, clinically significant cardiac 
murmur, body mass index, and heart failure into a risk prediction model for AF [51]. Among 
these factors, the PR interval on an electrocardiogram and clinically significant cardiac 
murmurs are not available in the CPRD.  
In conclusion, gout patients have a higher risk of AF at diagnosis and the risk is also higher 
afterwards. This study suggests an electrocardiogram as a part of the initial assessment of 
gout patients at diagnosis and close observation for the occurrence of incident AF after initial 
diagnosis of gout. 
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